Kadmon Holdings Inc (KDMN) Receives Average Rating of “Hold” from Brokerages

Share on StockTwits

Shares of Kadmon Holdings Inc (NYSE:KDMN) have earned an average recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $13.25.

KDMN has been the topic of several recent analyst reports. Zacks Investment Research lowered Kadmon from a “hold” rating to a “sell” rating in a research report on Tuesday, May 15th. ValuEngine raised Kadmon from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Jefferies Group upped their target price on Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, March 9th. Finally, Piper Jaffray Companies reaffirmed a “positive” rating and issued a $9.00 target price (up from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in KDMN. Verition Fund Management LLC bought a new stake in Kadmon during the 1st quarter valued at approximately $139,000. Citadel Advisors LLC boosted its stake in Kadmon by 181.3% during the 1st quarter. Citadel Advisors LLC now owns 49,500 shares of the company’s stock valued at $210,000 after purchasing an additional 31,906 shares during the period. Bank of New York Mellon Corp boosted its stake in Kadmon by 66.6% during the 4th quarter. Bank of New York Mellon Corp now owns 59,430 shares of the company’s stock valued at $216,000 after purchasing an additional 23,763 shares during the period. BlueCrest Capital Management Ltd bought a new stake in Kadmon during the 4th quarter valued at approximately $241,000. Finally, Wells Fargo & Company MN boosted its stake in Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after purchasing an additional 13,923 shares during the period. Institutional investors own 64.07% of the company’s stock.

Shares of Kadmon traded down $0.10, reaching $3.62, on Thursday, MarketBeat Ratings reports. 166,888 shares of the company were exchanged, compared to its average volume of 707,919. The firm has a market capitalization of $292.33 million, a PE ratio of -2.55 and a beta of 3.75. Kadmon has a fifty-two week low of $2.05 and a fifty-two week high of $5.86.

Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03. The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $2.67 million. equities analysts anticipate that Kadmon will post -1.12 earnings per share for the current fiscal year.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply